The Cancer Journey: A Patient and Caregiver Story
Jon Chait never thought he would get cancer, but one day he found he had it. As he navigates his journey alongside his caregiver and wife heather, he shares …
Related Articles
A Pragmatist’s View on Biomarker-Driven Decisions in Oncology: Episode 1
Website: https://www.onclive.comTwitter: https://twitter.com/OncLiveFacebook: https://www.facebook.com/OncLive/LinkedIn: https://www.linkedin.com/company/onc…
This Cautionary Colon Cancer Story Will Spark An Important Conversation
A new year means new chances to get ahead of your health! Patient advocate Candace Henley and medical oncologist Dr. Cathy Eng join the Tam…
9Health expert discusses the FDA’s ban of Red dye 3 due to potential cancer risk
Big changes are coming to our food supply! The FDA has officially banned Red Dye 3 due to its potential cancer risk. Tune in to…
Deep Learning Approach Characterizes Tumor Microenvironment in NSCLC | Docwire News
HistoTME, a novel deep learning approach, can characterize the tumor microenvironment molecular composition and predict responses to immune checkpoint inhibitors in NSCLC.
Biggest mortgage collapse in US History just got worse.
Homebuyer in demand in early 2025 has fallen again, with mortgage applications to buy a home down 63% from the pandemic peak.Access the price forecast…
Sotorasib Plus Panitumumab Approved by FDA for KRAS G12C-Mutated mCRC | Docwire News
The FDA has approved the combination of sotorasib with panitumumab for the treatment of KRAS G12C-mutated mCRC in adult patients who received certain prior treatments.
Critical Care Cardiology Education Summit
The 3rd annual Critical Care Cardiology Education Summit (CCCES) will be held June 4-6, 2025, on the University of Minnesota – East Bank campus. The…
KATHERINE Study: Trastuzumab Emtansine Enhances Survival in HER2 Breast Cancer | Docwire News
In patients with high-risk HER2-psoitive breast cancer, adjuvant trastuzumab emtansine reduces the long-term risk of death.
New Therapy Targets STAT3 in Chemotherapy-Resistant Leukemic Stem Cells in AML and MDS | Blood Cancers Today
By combining targeted approaches, there is potential to overcome resistance mechanisms and enhance durability of response in this high-risk AML and MDS.
ASCO Thanks Drs. Bertagnolli, Rathmell for Their Service Leading NIH,
The American Society of Clinical Oncology applauds Dr. Monica M. Bertagnolli for her service as the 17th Director of the National Institutes of Health and…
